血清 HE4 水平是上皮性卵巢癌的独立预后因素。

Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer.

机构信息

Hematologic Malignancies Branch, Research Institute and Hospital, Goyang, Republic of Korea.

出版信息

Ann Surg Oncol. 2012 May;19(5):1707-12. doi: 10.1245/s10434-011-1943-5. Epub 2011 Jul 21.

DOI:10.1245/s10434-011-1943-5

PMID:21833668

Abstract

BACKGROUND

This study was designed to determine whether serum HE4 is an independent prognostic factor in ovarian cancer patients.

METHODS

We measured HE4 in pretreatment serum samples from 80 women with epithelial ovarian cancer, using an enzyme-linked immunosorbent assay. The results were correlated with clinical data.

RESULTS

The median serum HE4 level in ovarian cancer patients was 98.7 (range, 80.3-222.8) pg/ml. Elevated serum HE4 levels before therapy significantly correlated with a poorer progression free survival (log-rank test, P = 0.017). Multivariate analysis revealed serum HE4 to be an independent prognostic factor for progression-free survival (P = 0.036). In multivariate regression analysis, high serum HE4 levels significantly correlated with high tumor grade and serous histology (P = 0.004 and 0.017). In addition, high serum HE4 levels were significantly associated with residual tumor size and operative time (P = 0.003 and 0.033).

CONCLUSIONS

Pretreatment serum HE4 seems to be an additional factor for predicting the outcome of patients with epithelial ovarian cancer. Due to its independence from established prognostic factors, serum HE4 may provide additional prognostic information.

摘要

背景

本研究旨在确定血清 HE4 是否为卵巢癌患者的独立预后因素。

方法

我们使用酶联免疫吸附试验测量了 80 名上皮性卵巢癌患者治疗前血清中的 HE4，将结果与临床数据相关联。

结果

卵巢癌患者的中位血清 HE4 水平为 98.7（范围 80.3-222.8）pg/ml。治疗前血清 HE4 水平升高与无进展生存期较差显著相关（对数秩检验，P=0.017）。多因素分析显示血清 HE4 是无进展生存期的独立预后因素（P=0.036）。在多因素回归分析中，高水平的血清 HE4 与高肿瘤分级和浆液性组织学显著相关（P=0.004 和 0.017）。此外，高水平的血清 HE4 与残留肿瘤大小和手术时间显著相关（P=0.003 和 0.033）。